Clear Search

Showing 1 result for “iberdomide biomarkers”.

June 2022

Biological impact of iberdomide in patients with active systemic lupus erythematosus

doi: 10.1136/annrheumdis-2022-222212

Phase 2b study evaluating the pharmacodynamics and pharmacokinetics of oral iberdomide in patients with active SLE demonstrates that iberdomide significantly improves lupus disease activity and reduces hallmarks of the immunopathogenesis of SLE.

more…